Julia Scarisbrick, MD

Articles by Julia Scarisbrick, MD

Dr Scarisbrick on Refining MF/Sézary Treatment With PROSPER Findings

June 27th 2026

Julia Scarisbrick, MD, explains how better recognition of mogamulizumab-associated rash is moving the drug earlier in the mycosis fungoides and Sézary treatment course.

Dr Scarisbrick on Mogamulizumab Outcomes in PROSPER

ByJulia Scarisbrick, MD

June 27th 2026

Julia Scarisbrick reviews real-world data showing mogamulizumab eased itch, pain, flaking, sleep, and fatigue in MF and Sézary syndrome as early as 4 weeks.

Julia Scarisbrick, MD

Articles by Julia Scarisbrick, MD

Dr Scarisbrick on Refining MF/Sézary Treatment With PROSPER Findings

Dr Scarisbrick on Mogamulizumab Outcomes in PROSPER

Latest Updated Articles

Trending on OncLive

Real-World Mogamulizumab Elicits Durable Responses in Pretreated Mycosis Fungoides and Sézary Syndrome

BI-1808 Shows Efficacy as Monotherapy and in Combination With Pembrolizumab in T-Cell Lymphomas

FDA Accepts Third RP1 BLA Resubmission With Nivolumab in Advanced Melanoma

From "Not Curable" to "May Be Curable": Joshua Richter, MD, on the New Reality of Multiple Myeloma

Dato-DXd Earns CHMP Positive Opinion for First-Line Metastatic TNBC